{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:29:10Z","timestamp":1792772950171,"version":"4.5.0"},"reference-count":285,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01232-0","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:56:41Z","timestamp":1792015001000},"page":"1494-1513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reframing cancer therapy through tumor plasticity"],"prefix":"10.1038","volume":"7","author":[{"given":"Akansha M.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-2584","authenticated-orcid":false,"given":"Frederic J.","family":"de Sauvage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1232_CR1","first-page":"622","volume":"10","author":"JB Gurdon","year":"1962","unstructured":"Gurdon, J. B. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J. Embryol. Exp. Morphol. 10, 622\u2013640 (1962).","journal-title":"J. Embryol. Exp. Morphol."},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663\u2013676 (2006).","journal-title":"Cell"},{"key":"1232_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi, S. & de Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39\u201356 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1232_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"\u00c1 Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga, \u00c1. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360\u2013371 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1232_CR5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A P\u00e9rez-Gonz\u00e1lez","year":"2023","unstructured":"P\u00e9rez-Gonz\u00e1lez, A., B\u00e9vant, K. & Blanpain, C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat. Cancer 4, 1063\u20131082 (2023).","journal-title":"Nat. Cancer"},{"key":"1232_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-024-07302-6","volume":"629","author":"P Karras","year":"2024","unstructured":"Karras, P., Black, J. R. M., McGranahan, N. & Marine, J.-C. Decoding the interplay between genetic and non-genetic drivers of metastasis. Nature 629, 543\u2013554 (2024).","journal-title":"Nature"},{"key":"1232_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3003052","volume":"23","author":"S Huang","year":"2025","unstructured":"Huang, S., Soto, A. M. & Sonnenschein, C. The end of the genetic paradigm of cancer. PLoS Biol. 23, e3003052 (2025).","journal-title":"PLoS Biol."},{"key":"1232_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1232_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1126\/science.1179386","volume":"326","author":"RL Yauch","year":"2009","unstructured":"Yauch, R. L. et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326, 572\u2013574 (2009).","journal-title":"Science"},{"key":"1232_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","volume":"23","author":"M Will","year":"2023","unstructured":"Will, M., Liang, J., Metcalfe, C. & Chandarlapaty, S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat. Rev. Cancer 23, 673\u2013685 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"1232_CR11","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","volume":"35","author":"J-K Lee","year":"2017","unstructured":"Lee, J.-K. et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J. Clin. Oncol. 35, 3065\u20133074 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR12","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492\u20132503 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR13","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo, W. et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162, 1271\u20131285 (2015).","journal-title":"Cell"},{"key":"1232_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10652-9","volume":"10","author":"CC Bell","year":"2019","unstructured":"Bell, C. C. et al. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nat. Commun. 10, 2723 (2019).","journal-title":"Nat. Commun."},{"key":"1232_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"J-C Marine","year":"2020","unstructured":"Marine, J.-C., Dawson, S.-J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743\u2013756 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1232_CR16","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-25-0999","volume":"85","author":"EA Oliveira","year":"2025","unstructured":"Oliveira, E. A. et al. Epigenetic heritability of cell plasticity drives cancer drug resistance through a one-to-many genotype-to-phenotype paradigm. Cancer Res. 85, 2921\u20132938 (2025).","journal-title":"Cancer Res."},{"key":"1232_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453\u2013457 (2017).","journal-title":"Nature"},{"key":"1232_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247\u2013250 (2017).","journal-title":"Nature"},{"key":"1232_CR19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2159-8290.CD-23-1161","volume":"14","author":"D Rosano","year":"2024","unstructured":"Rosano, D. et al. Long-term multimodal recording reveals epigenetic adaptation routes in dormant breast cancer cells. Cancer Discov. 14, 866\u2013889 (2024).","journal-title":"Cancer Discov."},{"key":"1232_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57429-x","volume":"16","author":"D Belenki","year":"2025","unstructured":"Belenki, D. et al. Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control. Nat. Commun. 16, 3079 (2025).","journal-title":"Nat. Commun."},{"key":"1232_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-018-0596-y","volume":"562","author":"B Biehs","year":"2018","unstructured":"Biehs, B. et al. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. Nature 562, 429\u2013433 (2018).","journal-title":"Nature"},{"key":"1232_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41588-024-02058-1","volume":"57","author":"S Mzoughi","year":"2025","unstructured":"Mzoughi, S. et al. Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer. Nat. Genet. 57, 402\u2013412 (2025).","journal-title":"Nat. Genet."},{"key":"1232_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","volume":"637","author":"A Moorman","year":"2025","unstructured":"Moorman, A. et al. Progressive plasticity during colorectal cancer metastasis. Nature 637, 947\u2013954 (2025).","journal-title":"Nature"},{"key":"1232_CR24","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473\u20131480 (2019).","journal-title":"Science"},{"key":"1232_CR25","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","volume":"12","author":"A Noronha","year":"2022","unstructured":"Noronha, A. et al. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discov. 12, 2666\u20132683 (2022).","journal-title":"Cancer Discov."},{"key":"1232_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","volume":"52","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat. Genet. 52, 891\u2013897 (2020).","journal-title":"Nat. Genet."},{"key":"1232_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature21356","volume":"543","author":"KM Turner","year":"2017","unstructured":"Turner, K. M. et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543, 122\u2013125 (2017).","journal-title":"Nature"},{"key":"1232_CR28","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41588-024-01949-7","volume":"56","author":"H Kim","year":"2024","unstructured":"Kim, H. et al. Mapping extrachromosomal DNA amplifications during cancer progression. Nat. Genet. 56, 2447\u20132454 (2024).","journal-title":"Nat. Genet."},{"key":"1232_CR29","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41588-022-01177-x","volume":"54","author":"JT Lange","year":"2022","unstructured":"Lange, J. T. et al. The evolutionary dynamics of extrachromosomal DNA in human cancers. Nat. Genet. 54, 1527\u20131533 (2022).","journal-title":"Nat. Genet."},{"key":"1232_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccell.2021.03.006","volume":"39","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription. Cancer Cell 39, 694\u2013707 (2021).","journal-title":"Cancer Cell"},{"key":"1232_CR31","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.88895.3","volume":"12","author":"MS Lin","year":"2024","unstructured":"Lin, M. S. et al. Transcriptional immune suppression and up-regulation of double-stranded DNA damage and repair repertoires in ecDNA-containing tumors. eLife 12, RP88895 (2024).","journal-title":"eLife"},{"key":"1232_CR32","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/2159-8290.CD-22-0787","volume":"13","author":"P Dharanipragada","year":"2023","unstructured":"Dharanipragada, P. et al. Blocking genomic instability prevents acquired resistance to MAPK inhibitor therapy in melanoma. Cancer Discov. 13, 880\u2013909 (2023).","journal-title":"Cancer Discov."},{"key":"1232_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"1232_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau, B. B. et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20, 233\u2013246 (2017).","journal-title":"Cell Stem Cell"},{"key":"1232_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-018-0603-3","volume":"562","author":"A S\u00e1nchez-Dan\u00e9s","year":"2018","unstructured":"S\u00e1nchez-Dan\u00e9s, A. et al. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature 562, 434\u2013438 (2018).","journal-title":"Nature"},{"key":"1232_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1158\/2159-8290.CD-24-0853","volume":"16","author":"DJ Yuan","year":"2026","unstructured":"Yuan, D. J. et al. Genotype-to-phenotype mapping of somatic clonal mosaicism via single-cell co-capture of DNA mutations and mRNA transcripts. Cancer Discov. 16, 721\u2013739 (2026).","journal-title":"Cancer Discov."},{"key":"1232_CR37","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1126\/science.aau0730","volume":"361","author":"J Cao","year":"2018","unstructured":"Cao, J. et al. Joint profiling of chromatin accessibility and gene expression in thousands of single cells. Science 361, 1380\u20131385 (2018).","journal-title":"Science"},{"key":"1232_CR38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41592-022-01461-y","volume":"19","author":"AF Chen","year":"2022","unstructured":"Chen, A. F. et al. NEAT-seq: simultaneous profiling of intra-nuclear proteins, chromatin accessibility and gene expression in single cells. Nat. Methods 19, 547\u2013553 (2022).","journal-title":"Nat. Methods"},{"key":"1232_CR39","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"1232_CR40","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232\u20131251 (2020).","journal-title":"Cell"},{"key":"1232_CR41","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","volume":"631","author":"GS Fran\u00e7a","year":"2024","unstructured":"Fran\u00e7a, G. S. et al. Cellular adaptation to cancer therapy along a resistance continuum. Nature 631, 876\u2013883 (2024).","journal-title":"Nature"},{"key":"1232_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2023.11.032","volume":"187","author":"D Kirschenbaum","year":"2024","unstructured":"Kirschenbaum, D. et al. Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell 187, 149\u2013165 (2024).","journal-title":"Cell"},{"key":"1232_CR43","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41588-025-02158-6","volume":"57","author":"W Yu","year":"2025","unstructured":"Yu, W. et al. Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring. Nat. Genet. 57, 1142\u20131154 (2025).","journal-title":"Nat. Genet."},{"key":"1232_CR44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843\u2013855 (2018).","journal-title":"Cell"},{"key":"1232_CR45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi, S. et al. Single-cell analysis of treatment-resistant prostate cancer: implications of cell state changes for cell surface antigen-targeted therapies. Proc. Natl Acad. Sci. USA 121, e2322203121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41576-023-00613-w","volume":"24","author":"J Lim","year":"2023","unstructured":"Lim, J. et al. Transitioning single-cell genomics into the clinic. Nat. Rev. Genet. 24, 573\u2013584 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"1232_CR47","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41586-018-0414-6","volume":"560","author":"G La Manno","year":"2018","unstructured":"La Manno, G. et al. RNA velocity of single cells. Nature 560, 494\u2013498 (2018).","journal-title":"Nature"},{"key":"1232_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41587-022-01476-y","volume":"41","author":"C Li","year":"2023","unstructured":"Li, C., Virgilio, M. C., Collins, K. L. & Welch, J. D. Multi-omic single-cell velocity models epigenome\u2013transcriptome interactions and improves cell fate prediction. Nat. Biotechnol. 41, 387\u2013398 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1232_CR49","doi-asserted-by":"publisher","first-page":"i394","DOI":"10.1093\/bioinformatics\/btad267","volume":"39","author":"C Burdziak","year":"2023","unstructured":"Burdziak, C. et al. scKINETICS: inference of regulatory velocity with single-cell transcriptomics data. Bioinformatics 39, i394\u2013i403 (2023).","journal-title":"Bioinformatics"},{"key":"1232_CR50","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41586-022-05194-y","volume":"609","author":"OS Rukhlenko","year":"2022","unstructured":"Rukhlenko, O. S. et al. Control of cell state transitions. Nature 609, 975\u2013985 (2022).","journal-title":"Nature"},{"key":"1232_CR51","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.cell.2022.04.015","volume":"185","author":"D Yang","year":"2022","unstructured":"Yang, D. et al. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell 185, 1905\u20131923 (2022).","journal-title":"Cell"},{"key":"1232_CR52","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.ccell.2021.05.005","volume":"39","author":"KP Simeonov","year":"2021","unstructured":"Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150\u20131162 (2021).","journal-title":"Cancer Cell"},{"key":"1232_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1944","volume":"371","author":"JJ Quinn","year":"2021","unstructured":"Quinn, J. J. et al. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science 371, eabc1944 (2021).","journal-title":"Science"},{"key":"1232_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115699","volume":"44","author":"LV Nguyen","year":"2025","unstructured":"Nguyen, L. V. et al. Fitness and transcriptional plasticity of human breast cancer single-cell-derived clones. Cell Rep. 44, 115699 (2025).","journal-title":"Cell Rep."},{"key":"1232_CR55","doi-asserted-by":"publisher","unstructured":"Salla, M. et al. Cryo-mtscATAC-seq for single-cell mitochondrial DNA genotyping and clonal tracing in archived human tissues. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.09.17.675534 (2025).","DOI":"10.1101\/2025.09.17.675534"},{"key":"1232_CR56","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s41587-022-01210-8","volume":"40","author":"TE Miller","year":"2022","unstructured":"Miller, T. E. et al. Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations. Nat. Biotechnol. 40, 1030\u20131034 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1232_CR57","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.cell.2019.01.022","volume":"176","author":"LS Ludwig","year":"2019","unstructured":"Ludwig, L. S. et al. Lineage tracing in humans enabled by mitochondrial mutations and single-cell genomics. Cell 176, 1325\u20131339 (2019).","journal-title":"Cell"},{"key":"1232_CR58","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.45105","volume":"8","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA. eLife 8, e45105 (2019).","journal-title":"eLife"},{"key":"1232_CR59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41587-020-0645-6","volume":"39","author":"CA Lareau","year":"2021","unstructured":"Lareau, C. A. et al. Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nat. Biotechnol. 39, 451\u2013461 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1232_CR60","doi-asserted-by":"publisher","unstructured":"Bracht, S. A. et al. Mitochondrial clone tracing within spatially intact human tissues. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.07.11.664452 (2025).","DOI":"10.1101\/2025.07.11.664452"},{"key":"1232_CR61","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41596-021-00556-8","volume":"16","author":"S Black","year":"2021","unstructured":"Black, S. et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat. Protoc. 16, 3802\u20133835 (2021).","journal-title":"Nat. Protoc."},{"key":"1232_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa6090","volume":"348","author":"KH Chen","year":"2015","unstructured":"Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S. & Zhuang, X. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 348, aaa6090 (2015).","journal-title":"Science"},{"key":"1232_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43458-x","volume":"14","author":"A Janesick","year":"2023","unstructured":"Janesick, A. et al. High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis. Nat. Commun. 14, 8353 (2023).","journal-title":"Nat. Commun."},{"key":"1232_CR64","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/s41587-022-01483-z","volume":"40","author":"S He","year":"2022","unstructured":"He, S. et al. High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. Nat. Biotechnol. 40, 1794\u20131806 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1232_CR65","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.cell.2020.05.039","volume":"182","author":"AL Ji","year":"2020","unstructured":"Ji, A. L. et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell 182, 497\u2013514 (2020).","journal-title":"Cell"},{"key":"1232_CR66","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41588-024-01890-9","volume":"56","author":"C Shiau","year":"2024","unstructured":"Shiau, C. et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat. Genet. 56, 2466\u20132478 (2024).","journal-title":"Nat. Genet."},{"key":"1232_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2025.100881","volume":"5","author":"S Ogden","year":"2025","unstructured":"Ogden, S. et al. Phenotypic heterogeneity and plasticity in colorectal cancer metastasis. Cell Genom. 5, 100881 (2025).","journal-title":"Cell Genom."},{"key":"1232_CR68","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s43018-026-01142-1","volume":"7","author":"CJ Frangieh","year":"2026","unstructured":"Frangieh, C. J. et al. Single-cell and spatial profiling in cancer biology and clinical oncology. Nat. Cancer 7, 597\u2013607 (2026).","journal-title":"Nat. Cancer"},{"key":"1232_CR69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.196","volume":"42","author":"C Sweeney","year":"2024","unstructured":"Sweeney, C. et al. Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC). J. Clin. Oncol. 42, 196 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.199","volume":"42","author":"CM Parseghian","year":"2024","unstructured":"Parseghian, C. M. et al. Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC). J. Clin. Oncol. 42, 199 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR71","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-24-1883","volume":"30","author":"AW Wyatt","year":"2024","unstructured":"Wyatt, A. W. et al. Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group. Clin. Cancer Res. 30, 5034\u20135041 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR72","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","volume":"3","author":"F Chemi","year":"2022","unstructured":"Chemi, F. et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat. Cancer 3, 1260\u20131270 (2022).","journal-title":"Nat. Cancer"},{"key":"1232_CR73","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2024.01.001","volume":"42","author":"S Heeke","year":"2024","unstructured":"Heeke, S. et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42, 225\u2013237 (2024).","journal-title":"Cancer Cell"},{"key":"1232_CR74","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tlcr-23-479","volume":"13","author":"S Park","year":"2024","unstructured":"Park, S. et al. Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses. Transl. Lung Cancer Res. 13, 280\u2013291 (2024).","journal-title":"Transl. Lung Cancer Res."},{"key":"1232_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk2082","volume":"10","author":"JB Hiatt","year":"2024","unstructured":"Hiatt, J. B. et al. Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions. Sci. Adv. 10, eadk2082 (2024).","journal-title":"Sci. Adv."},{"key":"1232_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-025-12083-x","volume":"26","author":"R Tamaki","year":"2025","unstructured":"Tamaki, R., Sagane, K., Li, S. D. & Hoshi, T. Cell-free DNA-based inference of the activities of 370 + transcription factors mirrors their activities in tumors. BMC Genomics 26, 892 (2025).","journal-title":"BMC Genomics"},{"key":"1232_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12714-4","volume":"10","author":"P Ulz","year":"2019","unstructured":"Ulz, P. et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat. Commun. 10, 4666 (2019).","journal-title":"Nat. Commun."},{"key":"1232_CR78","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41586-025-09580-0","volume":"647","author":"MJ Williams","year":"2025","unstructured":"Williams, M. J. et al. Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA. Nature 647, 757\u2013765 (2025).","journal-title":"Nature"},{"key":"1232_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2020.06.012","volume":"38","author":"ND Marjanovic","year":"2020","unstructured":"Marjanovic, N. D. et al. Emergence of a high-plasticity cell state during lung cancer evolution. Cancer Cell 38, 229\u2013246 (2020).","journal-title":"Cancer Cell"},{"key":"1232_CR80","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.devcel.2018.02.024","volume":"44","author":"PR Tata","year":"2018","unstructured":"Tata, P. R. et al. Developmental history provides a roadmap for the emergence of tumor plasticity. Dev. Cell 44, 679\u2013693 (2018).","journal-title":"Dev. Cell"},{"key":"1232_CR81","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/ng.465","volume":"41","author":"AJ Bass","year":"2009","unstructured":"Bass, A. J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238\u20131242 (2009).","journal-title":"Nat. Genet."},{"key":"1232_CR82","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nature06358","volume":"450","author":"BA Weir","year":"2007","unstructured":"Weir, B. A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893\u2013898 (2007).","journal-title":"Nature"},{"key":"1232_CR83","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-23-0289","volume":"14","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Cancer Discov. 14, 308\u2013325 (2023).","journal-title":"Cancer Discov."},{"key":"1232_CR84","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cell.2019.09.010","volume":"179","author":"Y Ouadah","year":"2019","unstructured":"Ouadah, Y. et al. Rare pulmonary neuroendocrine cells are stem cells regulated by Rb, p53, and Notch. Cell 179, 403\u2013416 (2019).","journal-title":"Cell"},{"key":"1232_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj1415","volume":"383","author":"EE Gardner","year":"2024","unstructured":"Gardner, E. E. et al. Lineage-specific intolerance to oncogenic drivers restricts histological transformation. Science 383, eadj1415 (2024).","journal-title":"Science"},{"key":"1232_CR86","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1101\/gad.314815.118","volume":"32","author":"Y-H Huang","year":"2018","unstructured":"Huang, Y.-H. et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 32, 915\u2013928 (2018).","journal-title":"Genes Dev."},{"key":"1232_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05428-x","volume":"13","author":"Y Yamada","year":"2022","unstructured":"Yamada, Y. et al. Pulmonary cancers across different histotypes share hybrid tuft cell\/ionocyte-like molecular features and potentially druggable vulnerabilities. Cell Death Dis. 13, 979 (2022).","journal-title":"Cell Death Dis."},{"key":"1232_CR88","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-025-09503-z","volume":"647","author":"AS Ireland","year":"2025","unstructured":"Ireland, A. S. et al. Basal cell of origin resolves neuroendocrine\u2013tuft lineage plasticity in cancer. Nature 647, 257\u2013267 (2025).","journal-title":"Nature"},{"key":"1232_CR89","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","volume":"560","author":"DT Montoro","year":"2018","unstructured":"Montoro, D. T. et al. A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 560, 319\u2013324 (2018).","journal-title":"Nature"},{"key":"1232_CR90","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-018-0394-6","volume":"560","author":"LW Plasschaert","year":"2018","unstructured":"Plasschaert, L. W. et al. A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. Nature 560, 377\u2013381 (2018).","journal-title":"Nature"},{"key":"1232_CR91","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay, C. M. et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39, 346\u2013360 (2021).","journal-title":"Cancer Cell"},{"key":"1232_CR92","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41591-019-0750-6","volume":"26","author":"AM Laughney","year":"2020","unstructured":"Laughney, A. M. et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat. Med. 26, 259\u2013269 (2020).","journal-title":"Nat. Med."},{"key":"1232_CR93","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.immuni.2018.02.001","volume":"48","author":"J Agudo","year":"2018","unstructured":"Agudo, J. et al. Quiescent tissue stem cells evade immune surveillance. Immunity 48, 271\u2013285 (2018).","journal-title":"Immunity"},{"key":"1232_CR94","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","volume":"165","author":"S Malladi","year":"2016","unstructured":"Malladi, S. et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45\u201360 (2016).","journal-title":"Cell"},{"key":"1232_CR95","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1073\/pnas.1012720108","volume":"108","author":"G Lapouge","year":"2011","unstructured":"Lapouge, G. et al. Identifying the cellular origin of squamous skin tumors. Proc. Natl Acad. Sci. USA 108, 7431\u20137436 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR96","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","volume":"18","author":"S Li","year":"2018","unstructured":"Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18, 767\u2013777 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1232_CR97","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.stem.2017.10.001","volume":"21","author":"JA Brown","year":"2017","unstructured":"Brown, J. A. et al. TGF-\u03b2-induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma. Cell Stem Cell 21, 650\u2013664 (2017).","journal-title":"Cell Stem Cell"},{"key":"1232_CR98","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","volume":"160","author":"N Oshimori","year":"2015","unstructured":"Oshimori, N., Oristian, D. & Fuchs, E. TGF-\u03b2 promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963\u2013976 (2015).","journal-title":"Cell"},{"key":"1232_CR99","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.cell.2019.03.025","volume":"177","author":"Y Miao","year":"2019","unstructured":"Miao, Y. et al. Adaptive immune resistance emerges from tumor-initiating stem cells. Cell 177, 1172\u20131186 (2019).","journal-title":"Cell"},{"key":"1232_CR100","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMc1715968","volume":"378","author":"H Pan","year":"2018","unstructured":"Pan, H. et al. Breast-cancer recurrence after stopping endocrine therapy. N. Engl. J. Med. 378, 870\u2013871 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR101","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nature20609","volume":"540","author":"KL Harper","year":"2016","unstructured":"Harper, K. L. et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature 540, 588\u2013592 (2016).","journal-title":"Nature"},{"key":"1232_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11721-9","volume":"10","author":"SP Hong","year":"2019","unstructured":"Hong, S. P. et al. Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. Nat. Commun. 10, 3840 (2019).","journal-title":"Nat. Commun."},{"key":"1232_CR103","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"TG Phan","year":"2020","unstructured":"Phan, T. G. & Croucher, P. I. The dormant cancer cell life cycle. Nat. Rev. Cancer 20, 398\u2013411 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1232_CR104","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41586-024-08285-0","volume":"637","author":"X Zhuang","year":"2025","unstructured":"Zhuang, X. et al. Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis. Nature 637, 184\u2013194 (2025).","journal-title":"Nature"},{"key":"1232_CR105","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","volume":"606","author":"E Mitchell","year":"2022","unstructured":"Mitchell, E. et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature 606, 343\u2013350 (2022).","journal-title":"Nature"},{"key":"1232_CR106","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","volume":"130","author":"F Zink","year":"2017","unstructured":"Zink, F. et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130, 742\u2013752 (2017).","journal-title":"Blood"},{"key":"1232_CR107","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s43018-024-00898-8","volume":"6","author":"J Liang","year":"2025","unstructured":"Liang, J. et al. ER\u03b1 dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer. Nat. Cancer 6, 357\u2013371 (2025).","journal-title":"Nat. Cancer"},{"key":"1232_CR108","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","volume":"18","author":"RC Doebele","year":"2012","unstructured":"Doebele, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472\u20131482 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR109","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","volume":"17","author":"AB Turke","year":"2010","unstructured":"Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77\u201388 (2010).","journal-title":"Cancer Cell"},{"key":"1232_CR110","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nm.3667","volume":"20","author":"CM Lovly","year":"2014","unstructured":"Lovly, C. M. et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med. 20, 1027\u20131034 (2014).","journal-title":"Nat. Med."},{"key":"1232_CR111","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim, C. et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173, 879\u2013893 (2018).","journal-title":"Cell"},{"key":"1232_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16212-w","volume":"11","author":"RV Velde","year":"2020","unstructured":"Velde, R. V. et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat. Commun. 11, 2393 (2020).","journal-title":"Nat. Commun."},{"key":"1232_CR113","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41586-023-06342-8","volume":"620","author":"Y Goyal","year":"2023","unstructured":"Goyal, Y. et al. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature 620, 651\u2013659 (2023).","journal-title":"Nature"},{"key":"1232_CR114","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ccell.2020.04.014","volume":"37","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy. Cancer Cell 37, 834\u2013849 (2020).","journal-title":"Cancer Cell"},{"key":"1232_CR115","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41586-025-09299-y","volume":"649","author":"J Jeong","year":"2026","unstructured":"Jeong, J. et al. NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. Nature 649, 205\u2013215 (2026).","journal-title":"Nature"},{"key":"1232_CR116","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","volume":"7","author":"JS Zawistowski","year":"2017","unstructured":"Zawistowski, J. S. et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 7, 302\u2013321 (2017).","journal-title":"Cancer Discov."},{"key":"1232_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05729-w","volume":"9","author":"T Risom","year":"2018","unstructured":"Risom, T. et al. Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat. Commun. 9, 3815 (2018).","journal-title":"Nat. Commun."},{"key":"1232_CR118","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ng.2913","volume":"46","author":"B Knoechel","year":"2014","unstructured":"Knoechel, B. et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 46, 364\u2013370 (2014).","journal-title":"Nat. Genet."},{"key":"1232_CR119","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","volume":"23","author":"A Roesch","year":"2013","unstructured":"Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells. Cancer Cell 23, 811\u2013825 (2013).","journal-title":"Cancer Cell"},{"key":"1232_CR120","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchembio.2085","volume":"12","author":"M Vinogradova","year":"2016","unstructured":"Vinogradova, M. et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat. Chem. Biol. 12, 531\u2013538 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"1232_CR121","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1078-0432.CCR-20-4054","volume":"27","author":"MM Tayari","year":"2021","unstructured":"Tayari, M. M. et al. Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin. Cancer Res. 27, 1893\u20131903 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR122","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84\u201388 (2017).","journal-title":"Science"},{"key":"1232_CR123","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"1232_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/celldisc.2015.26","volume":"1","author":"F Murai","year":"2015","unstructured":"Murai, F. et al. EZH2 promotes progression of small cell lung cancer by suppressing the TGF-\u03b2\u2013Smad\u2013ASCL1 pathway. Cell Discov. 1, 15026 (2015).","journal-title":"Cell Discov."},{"key":"1232_CR125","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41556-023-01210-z","volume":"25","author":"L Duplaquet","year":"2023","unstructured":"Duplaquet, L. et al. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer. Nat. Cell Biol. 25, 1346\u20131358 (2023).","journal-title":"Nat. Cell Biol."},{"key":"1232_CR126","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau2922","volume":"12","author":"A Augert","year":"2019","unstructured":"Augert, A. et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci. Signal. 12, eaau2922 (2019).","journal-title":"Sci. Signal."},{"key":"1232_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01572-3","volume":"17","author":"E Redin","year":"2024","unstructured":"Redin, E. et al. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J. Hematol. Oncol. 17, 58 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1232_CR128","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","volume":"83","author":"A Lundberg","year":"2023","unstructured":"Lundberg, A. et al. The genomic and epigenomic landscape of double-negative metastatic prostate cancer. Cancer Res. 83, 2763\u20132774 (2023).","journal-title":"Cancer Res."},{"key":"1232_CR129","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41422-024-01025-z","volume":"35","author":"F Li","year":"2025","unstructured":"Li, F. et al. LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer. Cell Res. 35, 59\u201371 (2025).","journal-title":"Cell Res."},{"key":"1232_CR130","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr, M. L. et al. An evolutionarily conserved function of Polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385\u2013401 (2019).","journal-title":"Cancer Cell"},{"key":"1232_CR131","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jtho.2022.05.014","volume":"17","author":"EM Nguyen","year":"2022","unstructured":"Nguyen, E. M. et al. Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC. J. Thorac. Oncol. 17, 1014\u20131031 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"1232_CR132","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.trecan.2026.01.011","volume":"12","author":"N Niu","year":"2026","unstructured":"Niu, N., Chen, M. & Xue, J. Epigenetic dysregulation and microenvironment remodeling in pancreatic cancer. Trends Cancer 12, 447\u2013460 (2026).","journal-title":"Trends Cancer"},{"key":"1232_CR133","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41586-025-09985-x","volume":"651","author":"JE Chan","year":"2026","unstructured":"Chan, J. E. et al. Critical role for a high-plasticity cell state in lung cancer. Nature 651, 231\u2013241 https:\/\/doi.org\/10.1038\/s41586-025-09985-x (2026).","journal-title":"Nature"},{"key":"1232_CR134","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"1232_CR135","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aas8779","volume":"12","author":"A Goldman","year":"2019","unstructured":"Goldman, A. et al. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Sci. Signal. 12, eaas8779 (2019).","journal-title":"Sci. Signal."},{"key":"1232_CR136","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s42255-019-0052-9","volume":"1","author":"WC Zhang","year":"2019","unstructured":"Zhang, W. C. et al. miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nat. Metab. 1, 460\u2013474 (2019).","journal-title":"Nat. Metab."},{"key":"1232_CR137","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi, J. et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell 33, 890\u2013904 (2018).","journal-title":"Cancer Cell"},{"key":"1232_CR138","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 (2010).","journal-title":"Nature"},{"key":"1232_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6712","volume":"5","author":"J M\u00fcller","year":"2014","unstructured":"M\u00fcller, J. et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 5, 5712 (2014).","journal-title":"Nat. Commun."},{"key":"1232_CR140","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF. Cancer Cell 23, 302\u2013315 (2013).","journal-title":"Cancer Cell"},{"key":"1232_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17739-8","volume":"11","author":"J Boshuizen","year":"2020","unstructured":"Boshuizen, J. et al. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nat. Commun. 11, 3946 (2020).","journal-title":"Nat. Commun."},{"key":"1232_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108421","volume":"33","author":"S Shen","year":"2020","unstructured":"Shen, S. et al. Melanoma persister cells are tolerant to BRAF\/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep. 33, 108421 (2020).","journal-title":"Cell Rep."},{"key":"1232_CR143","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s42255-023-00861-4","volume":"5","author":"M Redondo-Mu\u00f1oz","year":"2023","unstructured":"Redondo-Mu\u00f1oz, M. et al. Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy. Nat. Metab. 5, 1544\u20131562 (2023).","journal-title":"Nat. Metab."},{"key":"1232_CR144","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5683","volume":"12","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci. Transl. Med. 12, eaaz5683 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1232_CR145","doi-asserted-by":"publisher","unstructured":"Fr\u00f6se, J. et al. Tumor cell-intrinsic stress states drive sensitivity to CAR T cell-therapy in pancreatic cancer. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.07.24.666408 (2025).","DOI":"10.1101\/2025.07.24.666408"},{"key":"1232_CR146","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","volume":"33","author":"R Yaeger","year":"2018","unstructured":"Yaeger, R. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33, 125\u2013136 (2018).","journal-title":"Cancer Cell"},{"key":"1232_CR147","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.1016\/j.cell.2021.11.031","volume":"184","author":"B Chen","year":"2021","unstructured":"Chen, B. et al. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell 184, 6262\u20136280 (2021).","journal-title":"Cell"},{"key":"1232_CR148","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41588-022-01100-4","volume":"54","author":"I Joanito","year":"2022","unstructured":"Joanito, I. et al. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nat. Genet. 54, 963\u2013975 (2022).","journal-title":"Nat. Genet."},{"key":"1232_CR149","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.stem.2017.11.001","volume":"22","author":"S Yui","year":"2018","unstructured":"Yui, S. et al. YAP\/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell 22, 35\u201349 (2018).","journal-title":"Cell Stem Cell"},{"key":"1232_CR150","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.celrep.2013.09.005","volume":"5","author":"RC Mustata","year":"2013","unstructured":"Mustata, R. C. et al. Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Rep. 5, 421\u2013432 (2013).","journal-title":"Cell Rep."},{"key":"1232_CR151","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nature15382","volume":"526","author":"A Gregorieff","year":"2015","unstructured":"Gregorieff, A., Liu, Y., Inanlou, M. R., Khomchuk, Y. & Wrana, J. L. Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer. Nature 526, 715\u2013718 (2015).","journal-title":"Nature"},{"key":"1232_CR152","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature21713","volume":"543","author":"F de Sousa e Melo","year":"2017","unstructured":"de Sousa e Melo, F. et al. A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. Nature 543, 676\u2013680 (2017).","journal-title":"Nature"},{"key":"1232_CR153","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41586-025-09916-w","volume":"650","author":"M White","year":"2025","unstructured":"White, M. et al. MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance. Nature 650, 748\u2013758 https:\/\/doi.org\/10.1038\/s41586-025-09916-w (2025).","journal-title":"Nature"},{"key":"1232_CR154","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/s41588-026-02611-0","volume":"58","author":"AR Moore","year":"2026","unstructured":"Moore, A. R. et al. Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response. Nat. Genet. 58, 1331\u20131340 https:\/\/doi.org\/10.1038\/s41588-026-02611-0 (2026).","journal-title":"Nat. Genet."},{"key":"1232_CR155","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33\u201343 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR156","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR157","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med. 389, 710\u2013721 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR158","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads0239","volume":"389","author":"C Weller","year":"2025","unstructured":"Weller, C. et al. A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. Science 389, eads0239 (2025).","journal-title":"Science"},{"key":"1232_CR159","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/2159-8290.CD-25-0679","volume":"16","author":"A Centonze","year":"2026","unstructured":"Centonze, A. et al. A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRASG12D pharmacologic inhibition in metastatic colorectal cancer. Cancer Discov. 16, 320\u2013344 (2026).","journal-title":"Cancer Discov."},{"key":"1232_CR160","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccell.2025.10.010","volume":"44","author":"Y Zhang","year":"2026","unstructured":"Zhang, Y. et al. Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer Cell 44, 77\u201393 (2026).","journal-title":"Cancer Cell"},{"key":"1232_CR161","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","volume":"3","author":"A \u00c1lvarez-Varela","year":"2022","unstructured":"\u00c1lvarez-Varela, A. et al. Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nat. Cancer 3, 1052\u20131070 (2022).","journal-title":"Nat. Cancer"},{"key":"1232_CR162","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05402-9","volume":"611","author":"A Ca\u00f1ellas-Socias","year":"2022","unstructured":"Ca\u00f1ellas-Socias, A. et al. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells. Nature 611, 603\u2013613 (2022).","journal-title":"Nature"},{"key":"1232_CR163","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s43018-019-0006-x","volume":"1","author":"K Ganesh","year":"2020","unstructured":"Ganesh, K. et al. L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. Nat. Cancer 1, 28\u201345 (2020).","journal-title":"Nat. Cancer"},{"key":"1232_CR164","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s43018-026-01155-w","volume":"7","author":"M Heinlein","year":"2026","unstructured":"Heinlein, M. et al. A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer. Nat. Cancer 7, 899\u2013914 https:\/\/doi.org\/10.1038\/s43018-026-01155-w (2026).","journal-title":"Nat. Cancer"},{"key":"1232_CR165","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.stem.2020.02.008","volume":"26","author":"A Fumagalli","year":"2020","unstructured":"Fumagalli, A. et al. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell 26, 569\u2013578 (2020).","journal-title":"Cell Stem Cell"},{"key":"1232_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05626-2","volume":"9","author":"RR Arasada","year":"2018","unstructured":"Arasada, R. R. et al. Notch3-dependent \u03b2-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nat. Commun. 9, 3198 (2018).","journal-title":"Nat. Commun."},{"key":"1232_CR167","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/0008-5472.CAN-11-2848","volume":"72","author":"M Cas\u00e1s-Selves","year":"2012","unstructured":"Cas\u00e1s-Selves, M. et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 72, 4154\u20134164 (2012).","journal-title":"Cancer Res."},{"key":"1232_CR168","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-14-0184","volume":"74","author":"S Nakayama","year":"2014","unstructured":"Nakayama, S. et al. \u03b2-Catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res. 74, 5891\u20135902 (2014).","journal-title":"Cancer Res."},{"key":"1232_CR169","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm.2890","volume":"18","author":"Y Sun","year":"2012","unstructured":"Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18, 1359\u20131368 (2012).","journal-title":"Nat. Med."},{"key":"1232_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.61","volume":"2","author":"M Saxena","year":"2011","unstructured":"Saxena, M., Stephens, M. A., Pathak, H. & Rangarajan, A. Transcription factors that mediate epithelial\u2013mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2, e179 (2011).","journal-title":"Cell Death Dis."},{"key":"1232_CR171","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1158\/1535-7163.MCT-13-0170","volume":"12","author":"KM Giles","year":"2013","unstructured":"Giles, K. M. et al. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther. 12, 2541\u20132558 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"1232_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21061-1","volume":"8","author":"YK Chae","year":"2018","unstructured":"Chae, Y. K. et al. Epithelial\u2013mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Sci. Rep. 8, 2918 (2018).","journal-title":"Sci. Rep."},{"key":"1232_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.10.012","volume":"139","author":"JC Thompson","year":"2020","unstructured":"Thompson, J. C. et al. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer 139, 1\u20138 (2020).","journal-title":"Lung Cancer"},{"key":"1232_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03239-1","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma. Stem Cell Res. Ther. 14, 15 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"1232_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02121-7","volume":"10","author":"M Yadav","year":"2025","unstructured":"Yadav, M. et al. AXL signaling in cancer: from molecular insights to targeted therapies. Signal Transduct. Target. Ther. 10, 37 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1232_CR176","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers, L. A. et al. An epithelial\u2013mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279\u2013290 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100554","volume":"3","author":"H Li","year":"2022","unstructured":"Li, H. et al. AXL targeting restores PD-1 blockade sensitivity of STK11\/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. Cell Rep. Med. 3, 100554 (2022).","journal-title":"Cell Rep. Med."},{"key":"1232_CR178","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1158\/1078-0432.CCR-20-3872","volume":"27","author":"HS Solanki","year":"2021","unstructured":"Solanki, H. S. et al. Cell type-specific adaptive signaling responses to KRASG12C inhibition. Clin. Cancer Res. 27, 2533\u20132548 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR179","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","volume":"26","author":"Y Adachi","year":"2020","unstructured":"Adachi, Y. et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin. Cancer Res. 26, 5962\u20135973 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR180","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaw9450","volume":"12","author":"K Lou","year":"2019","unstructured":"Lou, K. et al. KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Sci. Signal. 12, eaaw9450 (2019).","journal-title":"Sci. Signal."},{"key":"1232_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216692","volume":"587","author":"K Morimoto","year":"2024","unstructured":"Morimoto, K. et al. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells. Cancer Lett. 587, 216692 (2024).","journal-title":"Cancer Lett."},{"key":"1232_CR182","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/1535-7163.MCT-13-0775","volume":"13","author":"M Mar\u00edn-Aguilera","year":"2014","unstructured":"Mar\u00edn-Aguilera, M. et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol. Cancer Ther. 13, 1270\u20131284 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"1232_CR183","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/0008-5472.CAN-15-2078","volume":"76","author":"SK Martin","year":"2016","unstructured":"Martin, S. K. et al. Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer. Cancer Res. 76, 912\u2013926 (2016).","journal-title":"Cancer Res."},{"key":"1232_CR184","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1158\/1078-0432.CCR-10-0593","volume":"16","author":"DS-S Hsu","year":"2010","unstructured":"Hsu, D. S.-S. et al. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin. Cancer Res. 16, 4561\u20134571 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR185","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003484","volume":"10","author":"M Plaschka","year":"2022","unstructured":"Plaschka, M. et al. ZEB1 transcription factor promotes immune escape in melanoma. J. Immunother. Cancer 10, e003484 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1232_CR186","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.18.01585","volume":"37","author":"N Marcoux","year":"2019","unstructured":"Marcoux, N. et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J. Clin. Oncol. 37, 278\u2013285 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR187","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2010.05.026","volume":"42","author":"CC Guo","year":"2011","unstructured":"Guo, C. C. et al. TMPRSS2\u2013ERG gene fusion in small cell carcinoma of the prostate. Hum. Pathol. 42, 11\u201317 (2011).","journal-title":"Hum. Pathol."},{"key":"1232_CR188","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487\u2013495 (2011).","journal-title":"Cancer Discov."},{"key":"1232_CR189","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/2159-8290.CD-16-1174","volume":"7","author":"M Zou","year":"2017","unstructured":"Zou, M. et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 7, 736\u2013749 (2017).","journal-title":"Cancer Discov."},{"key":"1232_CR190","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop, J. L. et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54\u201371 (2017).","journal-title":"Cancer Discov."},{"key":"1232_CR191","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan, J. M. et al. Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science 377, 1180\u20131191 (2022).","journal-title":"Science"},{"key":"1232_CR192","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/annonc\/mdw032","volume":"27","author":"N Takegawa","year":"2016","unstructured":"Takegawa, N. et al. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann. Oncol. 27, 953\u2013955 (2016).","journal-title":"Ann. Oncol."},{"key":"1232_CR193","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a002394","volume":"4","author":"A Balla","year":"2018","unstructured":"Balla, A., Khan, F., Hampel, K. J., Aisner, D. L. & Sidiropoulos, N. Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung. Cold Spring Harb. Mol. Case Stud. 4, a002394 (2018).","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"1232_CR194","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nm.4494","volume":"24","author":"P Roswall","year":"2018","unstructured":"Roswall, P. et al. Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nat. Med. 24, 463\u2013473 (2018).","journal-title":"Nat. Med."},{"key":"1232_CR195","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ccr.2014.04.024","volume":"25","author":"S Yamamoto","year":"2014","unstructured":"Yamamoto, S. et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell 25, 762\u2013777 (2014).","journal-title":"Cancer Cell"},{"key":"1232_CR196","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/onc.2012.62","volume":"32","author":"GM Bernardo","year":"2013","unstructured":"Bernardo, G. M. et al. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 32, 554\u2013563 (2013).","journal-title":"Oncogene"},{"key":"1232_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-0151-5","volume":"6","author":"F Bertucci","year":"2020","unstructured":"Bertucci, F., Finetti, P., Goncalves, A. & Birnbaum, D. The therapeutic response of ER+\/HER2\u2212 breast cancers differs according to the molecular basal or luminal subtype. NPJ Breast Cancer 6, 8 (2020).","journal-title":"NPJ Breast Cancer"},{"key":"1232_CR198","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07188-9","volume":"9","author":"F Han","year":"2018","unstructured":"Han, F. et al. The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat. Commun. 9, 4728 (2018).","journal-title":"Nat. Commun."},{"key":"1232_CR200","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ccell.2015.04.001","volume":"27","author":"F Li","year":"2015","unstructured":"Li, F. et al. LKB1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response. Cancer Cell 27, 698\u2013711 (2015).","journal-title":"Cancer Cell"},{"key":"1232_CR201","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41556-024-01498-5","volume":"26","author":"H Tamagawa","year":"2024","unstructured":"Tamagawa, H. et al. Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma. Nat. Cell Biol. 26, 1759\u20131772 (2024).","journal-title":"Nat. Cell Biol."},{"key":"1232_CR202","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1073\/pnas.1016030108","volume":"108","author":"Y Soda","year":"2011","unstructured":"Soda, Y. et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl Acad. Sci. USA 108, 4274\u20134280 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR203","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/brain\/awq044","volume":"133","author":"S El Hallani","year":"2010","unstructured":"El Hallani, S. et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133, 973\u2013982 (2010).","journal-title":"Brain"},{"key":"1232_CR204","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1172\/JCI84876","volume":"126","author":"M Huang","year":"2016","unstructured":"Huang, M. et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J. Clin. Invest. 126, 1801\u20131814 (2016).","journal-title":"J. Clin. Invest."},{"key":"1232_CR205","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699\u2013708 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR206","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733\u20134740 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR207","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S0140-6736(00)02241-8","volume":"355","author":"E Gunsilius","year":"2000","unstructured":"Gunsilius, E. et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355, 1688\u20131691 (2000).","journal-title":"Lancet"},{"key":"1232_CR208","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1056\/NEJMoa033153","volume":"351","author":"B Streubel","year":"2004","unstructured":"Streubel, B. et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 351, 250\u2013259 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR209","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2006.09.0696","volume":"25","author":"A Pezzolo","year":"2007","unstructured":"Pezzolo, A. et al. Tumor origin of endothelial cells in human neuroblastoma. J. Clin. Oncol. 25, 376\u2013383 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR210","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1582-4934.2008.00338.x","volume":"13","author":"B Bussolati","year":"2009","unstructured":"Bussolati, B., Grange, C., Sapino, A. & Camussi, G. Endothelial cell differentiation of human breast tumour stem\/progenitor cells. J. Cell. Mol. Med. 13, 309\u2013319 (2009).","journal-title":"J. Cell. Mol. Med."},{"key":"1232_CR211","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","volume":"155","author":"AJ Maniotis","year":"1999","unstructured":"Maniotis, A. J. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739\u2013752 (1999).","journal-title":"Am. J. Pathol."},{"key":"1232_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13322","volume":"7","author":"SC Williamson","year":"2016","unstructured":"Williamson, S. C. et al. Vasculogenic mimicry in small cell lung cancer. Nat. Commun. 7, 13322 (2016).","journal-title":"Nat. Commun."},{"key":"1232_CR213","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05982-z","volume":"9","author":"T Liu","year":"2018","unstructured":"Liu, T. et al. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nat. Commun. 9, 3439 (2018).","journal-title":"Nat. Commun."},{"key":"1232_CR214","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR215","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1232_CR216","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"1232_CR217","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/pbc.25953","volume":"63","author":"A Rayes","year":"2016","unstructured":"Rayes, A., McMasters, R. L. & O\u2019Brien, M. M. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer 63, 1113\u20131115 (2016).","journal-title":"Pediatr. Blood Cancer"},{"key":"1232_CR218","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7, 12320 (2016).","journal-title":"Nat. Commun."},{"key":"1232_CR219","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"1232_CR220","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","volume":"9","author":"G de Oliveira Canedo","year":"2025","unstructured":"de Oliveira Canedo, G., Roddie, C. & Amrolia, P. J. Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Blood Adv. 9, 704\u2013721 (2025).","journal-title":"Blood Adv."},{"key":"1232_CR221","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ccell.2021.05.015","volume":"39","author":"O Marin-Bejar","year":"2021","unstructured":"Marin-Bejar, O. et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell 39, 1135\u20131149 (2021).","journal-title":"Cancer Cell"},{"key":"1232_CR222","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20166796","volume":"13","author":"M Fallahi-Sichani","year":"2017","unstructured":"Fallahi-Sichani, M. et al. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol. Syst. Biol. 13, MSB166796 (2017).","journal-title":"Mol. Syst. Biol."},{"key":"1232_CR223","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","volume":"8","author":"A Mehta","year":"2018","unstructured":"Mehta, A. et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 8, 935\u2013943 (2018).","journal-title":"Cancer Discov."},{"key":"1232_CR224","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15726-7","volume":"11","author":"JH Lee","year":"2020","unstructured":"Lee, J. H. et al. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat. Commun. 11, 1897 (2020).","journal-title":"Nat. Commun."},{"key":"1232_CR225","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg, J. et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490, 412\u2013416 (2012).","journal-title":"Nature"},{"key":"1232_CR226","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41556-020-0547-3","volume":"22","author":"J Wouters","year":"2020","unstructured":"Wouters, J. et al. Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nat. Cell Biol. 22, 986\u2013998 (2020).","journal-title":"Nat. Cell Biol."},{"key":"1232_CR227","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder, M. et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 21, 1423\u20131432 (2020).","journal-title":"Lancet Oncol."},{"key":"1232_CR228","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/2159-8290.CD-23-0110","volume":"14","author":"Y Kazansky","year":"2024","unstructured":"Kazansky, Y. et al. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer Discov. 14, 965\u2013981 (2024).","journal-title":"Cancer Discov."},{"key":"1232_CR229","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-7182","volume":"85","author":"S Sharma","year":"2025","unstructured":"Sharma, S. et al. Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamide. Cancer Res. 85, 7182 (2025).","journal-title":"Cancer Res."},{"key":"1232_CR230","volume":"43","author":"MT Schweizer","year":"2025","unstructured":"Schweizer, M. T. et al. Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): a randomized dose-expansion study. J. Clin. Oncol. 43, LBA138 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR231","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-452","volume":"85","author":"A Daemen","year":"2025","unstructured":"Daemen, A. et al. Abstract 452: ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors. Cancer Res. 85, 452 (2025).","journal-title":"Cancer Res."},{"key":"1232_CR232","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","volume":"560","author":"JB Baell","year":"2018","unstructured":"Baell, J. B. et al. Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth. Nature 560, 253\u2013257 (2018).","journal-title":"Nature"},{"key":"1232_CR233","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41591-024-03060-0","volume":"30","author":"T Mukohara","year":"2024","unstructured":"Mukohara, T. et al. Inhibition of lysine acetyltransferase KAT6 in ER+HER2\u2212 metastatic breast cancer: a phase 1 trial. Nat. Med. 30, 2242\u20132250 (2024).","journal-title":"Nat. Med."},{"key":"1232_CR234","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1020","volume":"43","author":"P LoRusso","year":"2025","unstructured":"LoRusso, P. et al. Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+\/HER2\u2212 metastatic breast cancer (mBC): results from phase 1 study to support the recommended phase 3 dose (RP3D). J. Clin. Oncol. 43, 1020 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR235","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera, A., O\u2019Byrne, K. J. & Richard, D. J. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 44, 37 (2025).","journal-title":"Cancer Metastasis Rev."},{"key":"1232_CR236","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02598-5","volume":"20","author":"P Zhang","year":"2022","unstructured":"Zhang, P. et al. Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Med. 20, 435 (2022).","journal-title":"BMC Med."},{"key":"1232_CR237","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52528-7","volume":"15","author":"M Baretti","year":"2024","unstructured":"Baretti, M. et al. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Nat. Commun. 15, 9801 (2024).","journal-title":"Nat. Commun."},{"key":"1232_CR238","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-013-2784-7","volume":"143","author":"P Shah","year":"2014","unstructured":"Shah, P., Gau, Y. & Sabnis, G. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res. Treat. 143, 99\u2013111 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"1232_CR239","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1038\/onc.2015.444","volume":"35","author":"M Ruscetti","year":"2016","unstructured":"Ruscetti, M. et al. HDAC inhibition impedes epithelial\u2013mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene 35, 3781\u20133795 (2016).","journal-title":"Oncogene"},{"key":"1232_CR240","first-page":"4479","volume":"9","author":"S Herbertz","year":"2015","unstructured":"Herbertz, S. et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-\u03b2 signaling pathway. Drug Des. Devel. Ther. 9, 4479\u20134499 (2015).","journal-title":"Drug Des. Devel. Ther."},{"key":"1232_CR241","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111046","volume":"134","author":"C-Y Huang","year":"2021","unstructured":"Huang, C.-Y. et al. Recent progress in TGF-\u03b2 inhibitors for cancer therapy. Biomed. Pharmacother. 134, 111046 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"1232_CR242","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","volume":"23","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki, T. et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol. 23, 1189\u20131200 (2022).","journal-title":"Lancet Oncol."},{"key":"1232_CR243","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1158\/0008-5472.CAN-21-3565","volume":"82","author":"Y Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez, Y. et al. A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer. Cancer Res. 82, 2110\u20132123 (2022).","journal-title":"Cancer Res."},{"key":"1232_CR244","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1158\/2767-9764.CRC-22-0194","volume":"2","author":"VK Morris","year":"2022","unstructured":"Morris, V. K. et al. Bintrafusp alfa, an anti-PD-L1:TGF-\u03b2 trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res. Commun. 2, 979\u2013986 (2022).","journal-title":"Cancer Res. Commun."},{"key":"1232_CR245","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ccell.2016.01.001","volume":"29","author":"M Grandin","year":"2016","unstructured":"Grandin, M. et al. Structural decoding of the Netrin-1\/UNC5 interaction and its therapeutical implications in cancers. Cancer Cell 29, 173\u2013185 (2016).","journal-title":"Cancer Cell"},{"key":"1232_CR246","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41586-023-06367-z","volume":"620","author":"PA Cassier","year":"2023","unstructured":"Cassier, P. A. et al. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature 620, 409\u2013416 (2023).","journal-title":"Nature"},{"key":"1232_CR247","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41586-026-10436-4","volume":"654","author":"G Roth","year":"2026","unstructured":"Roth, G. et al. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Nature 654, 798\u2013805 https:\/\/doi.org\/10.1038\/s41586-026-10436-4 (2026).","journal-title":"Nature"},{"key":"1232_CR248","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. & Wang, X. Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. J. Hematol. Oncol. 13, 165 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1232_CR249","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.286","volume":"43","author":"AB El-Khoueiry","year":"2025","unstructured":"El-Khoueiry, A. B. et al. Safety and biomarker assessment of ST316, a novel peptide antagonist of \u03b2-catenin, in patients with advanced solid tumors. J. Clin. Oncol. 43, 286 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR250","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.11523","volume":"40","author":"LD Cranmer","year":"2022","unstructured":"Cranmer, L. D. et al. Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor. J. Clin. Oncol. 40, 11523 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR251","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3175","volume":"42","author":"KP Papadopoulos","year":"2024","unstructured":"Papadopoulos, K. P. et al. A first-in-human, phase 1\/2 trial of FOG-001, a \u03b2-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors. J. Clin. Oncol. 42, TPS3175 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR252","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-25-B031","volume":"24","author":"SJ Klempner","year":"2025","unstructured":"Klempner, S. J. et al. Abstract B031: a phase 1\/2 trial of FOG-001, a first-in-class direct \u03b2-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+). Mol. Cancer Ther. 24, B031 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"1232_CR253","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101665","volume":"17","author":"AS Lundberg","year":"2025","unstructured":"Lundberg, A. S. et al. Petosemtamab, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and leucine-rich G repeat-containing protein-coupled receptor (LGR5) designed for broad clinical applications. Cancers (Basel) 17, 1665 (2025).","journal-title":"Cancers (Basel)"},{"key":"1232_CR254","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1080\/14796694.2025.2511470","volume":"21","author":"J-P Machiels","year":"2025","unstructured":"Machiels, J.-P. et al. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 21, 2007\u20132016 (2025).","journal-title":"Future Oncol."},{"key":"1232_CR255","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8565","volume":"42","author":"MF Chen","year":"2024","unstructured":"Chen, M. F. et al. Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations. J. Clin. Oncol. 42, 8565 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR256","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01131-0","volume":"9","author":"C Lin","year":"2025","unstructured":"Lin, C. et al. The evolving landscape of antibody\u2013drug conjugates (ADCs) for treatment of prostate cancer. NPJ Precis. Oncol. 9, 351 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"1232_CR257","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00784-7","volume":"9","author":"A Ajay","year":"2025","unstructured":"Ajay, A. et al. Assessment of targets of antibody drug conjugates in SCLC. NPJ Precis. Oncol. 9, 1 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"1232_CR258","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20251652","volume":"223","author":"PA Baeuerle","year":"2025","unstructured":"Baeuerle, P. A., Sauer, K., Grieshaber-Bouyer, R. & Michaelson, J. S. T cell engagers emerge as a compelling therapeutic modality. J. Exp. Med. 223, e20251652 (2025).","journal-title":"J. Exp. Med."},{"key":"1232_CR259","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1073\/pnas.1905384117","volume":"117","author":"E-C Hsu","year":"2020","unstructured":"Hsu, E.-C. et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc. Natl Acad. Sci. USA 117, 2032\u20132042 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1232_CR260","doi-asserted-by":"publisher","first-page":"S993","DOI":"10.1016\/j.annonc.2024.08.1729","volume":"35","author":"JM Lang","year":"2024","unstructured":"Lang, J. M. et al. 1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI). Ann. Oncol. 35, S993\u2013S994 (2024).","journal-title":"Ann. Oncol."},{"key":"1232_CR261","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.171","volume":"43","author":"G Von Amsberg","year":"2025","unstructured":"Von Amsberg, G. et al. Targeting TROP2 in aggressive variant and neuroendocrine prostate cancer. J. Clin. Oncol. 43, 171 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR262","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101707","volume":"5","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Phase 1a study of ESG401, a Trop2 antibody\u2013drug conjugate, in patients with locally advanced\/metastatic solid tumors. Cell Rep. Med. 5, 101707 (2024).","journal-title":"Cell Rep. Med."},{"key":"1232_CR263","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472794","volume":"45","author":"A Aijaz","year":"2025","unstructured":"Aijaz, A. et al. Taking a bite out of small cell lung cancer by leveraging precision-directed delta-like ligand-3 therapies. Am. Soc. Clin. Oncol. Educ. Book 45, e472794 (2025).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1232_CR264","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"M-J Ahn","year":"2023","unstructured":"Ahn, M.-J. et al. Tarlatamab for patients with previously treated small-cell lung cancer. N. Engl. J. Med. 389, 2063\u20132075 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR265","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios, G. et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N. Engl. J. Med. 393, 349\u2013361 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1232_CR266","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang, Z. et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 806\u2013815 (2019).","journal-title":"Lancet Oncol."},{"key":"1232_CR267","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","volume":"13","author":"B Xu","year":"2023","unstructured":"Xu, B. et al. Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Acta Pharm. Sin. B 13, 2250\u20132258 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"1232_CR268","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/13543776.2025.2468792","volume":"35","author":"J Zhang","year":"2025","unstructured":"Zhang, J., Ren, X., Song, Y. & Yu, B. JBI-802: the first orally available LSD1\/HDAC6 dual inhibitor to enter clinical trials. Expert Opin. Ther. Pat. 35, 493\u2013501 (2025).","journal-title":"Expert Opin. Ther. Pat."},{"key":"1232_CR269","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1158\/1078-0432.CCR-24-2583","volume":"31","author":"JA Livingston","year":"2025","unstructured":"Livingston, J. A. et al. A phase I study of FHD-609, a heterobifunctional degrader of bromodomain-containing protein 9, in patients with advanced synovial sarcoma or SMARCB1-deficient tumors. Clin. Cancer Res. 31, 628\u2013638 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR270","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41586-023-06372-2","volume":"620","author":"J Lengrand","year":"2023","unstructured":"Lengrand, J. et al. Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature 620, 402\u2013408 (2023).","journal-title":"Nature"},{"key":"1232_CR271","doi-asserted-by":"publisher","first-page":"S819","DOI":"10.1016\/j.annonc.2023.09.2471","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip, E. et al. 1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571). Ann. Oncol. 34, S819 (2023).","journal-title":"Ann. Oncol."},{"key":"1232_CR272","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107291","volume":"182","author":"S Bhalla","year":"2023","unstructured":"Bhalla, S. et al. Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer 182, 107291 (2023).","journal-title":"Lung Cancer"},{"key":"1232_CR273","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/j.annonc.2025.05.189","volume":"36","author":"D Li","year":"2025","unstructured":"Li, D. et al. 176P Tegavivint, a downstream Wnt\/\u03b2-catenin inhibitor: interim results from a phase I\/II trial in advanced hepatocellular carcinoma (aHCC). Ann. Oncol. 36, S74 (2025).","journal-title":"Ann. Oncol."},{"key":"1232_CR274","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.196","volume":"41","author":"PG Pili\u00e9","year":"2023","unstructured":"Pili\u00e9, P. G. et al. Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel\u2013carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC). J. Clin. Oncol. 41, 196 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR275","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5008","volume":"43","author":"A Aparicio","year":"2025","unstructured":"Aparicio, A. et al. C3NIRA: randomized phase II study of carboplatin\u2013cabazitaxel\u2013cetrelimab (anti-PD-1) induction followed by niraparib +\/\u2212 cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC). J. Clin. Oncol. 43, 5008 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1044","volume":"43","author":"F Ma","year":"2025","unstructured":"Ma, F. et al. Comprehensive results of ESG401, a TROP2-targeting ADC: updated phase 1 analysis in advanced solid tumors. J. Clin. Oncol. 43, 1044 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR277","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall, F. et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. J. Thorac. Oncol. 16, 1547\u20131558 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1232_CR278","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","volume":"16","author":"ML Johnson","year":"2021","unstructured":"Johnson, M. L. et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. J. Thorac. Oncol. 16, 1570\u20131581 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1232_CR279","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","volume":"31","author":"R Aggarwal","year":"2025","unstructured":"Aggarwal, R. et al. Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study. Clin. Cancer Res. 31, 3854\u20133863 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1232_CR280","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO-25-00363","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke, M. et al. Phase I dose-escalation results for the delta-like ligand 3\/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with delta-like ligand 3+ small cell lung cancer or neuroendocrine carcinomas. J. Clin. Oncol. 43, 3021\u20133031 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR281","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.121","volume":"42","author":"H Beltran","year":"2024","unstructured":"Beltran, H. et al. Interim results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). J. Clin. Oncol. 42, 121 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1232_CR282","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0356-4","volume":"6","author":"RB Holmgaard","year":"2018","unstructured":"Holmgaard, R. B. et al. Targeting the TGF\u03b2 pathway with galunisertib, a TGF\u03b2RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J. Immunother. Cancer 6, 47 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1232_CR283","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-026-08581-9","volume":"17","author":"M Cucchiara","year":"2026","unstructured":"Cucchiara, M. et al. The TGF-\u03b2R1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization. Cell Death Dis. 17, 577 https:\/\/doi.org\/10.1038\/s41419-026-08581-9 (2026).","journal-title":"Cell Death Dis."},{"key":"1232_CR284","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51442-2","volume":"15","author":"E Malek","year":"2024","unstructured":"Malek, E. et al. The TGF\u03b2 type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed\/refractory multiple myeloma: a phase 1b trial. Nat. Commun. 15, 7388 (2024).","journal-title":"Nat. Commun."},{"key":"1232_CR285","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-6046","volume":"82","author":"K Nakahata","year":"2022","unstructured":"Nakahata, K., Nirala, B. K., Shuck, R. L., Kurenbekova, L. & Yustein, J. T. Abstract 6046: targeting TBL1 inhibits nuclear \u03b2-catenin activity and enhances immune checkpoint inhibition efficacy in osteosarcoma. Cancer Res. 82, 6046 (2022).","journal-title":"Cancer Res."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01232-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01232-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01232-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:02:04Z","timestamp":1792764124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01232-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":285,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01232-0","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.S., B.P.M. and F.J.d.S. are employees of Genentech, Inc., and own Roche shares.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}